The main aim of this study was to set up a new animal model to study insulin resistance. Wistar rats (6-7 for group) received for 4 weeks in EXPERIMENT 1: A) Vehicle, B) 2µg/day subcutaneous Dexamethasone, C) Metformin 400 mg/Kg/day per os, and D) Dexamethasone + Metformin; while in EXPERIMENT 2: A) Vehicle, B) Dexamethasone, C) Dexamethasone + Arginine 2% (as substrate of the nitric oxide synthase for nitric oxide production) in tap water and D) Dexamethasone + Isosorbide dinitrate 70 mg/Kg (as direct nitric oxide donor) in tap water. Insulin sensitivity was significantly reduced by Dexamethasone already at week 1, before the increase in blood pressure (day 15) without significant changes in body weight as compared to vehicle. Dexamethasone treated rats had significantly higher triglycerides, haematocrit and insulin while serum total nitrates/nitrites were lower as compared to vehicle. The concomitant treatment with metformin minified all the described effects of dexamethasone. In experiment 2 only isosorbide dinitrate was able to prevent the observed dexamethasone induced metabolic, haemodynamic and insulin sensitivity changes. Chronic low dose subcutaneous dexamethasone (2µg/day) is an useful model to studying the relationships between insulin resistance and blood pressure in the rat and dexamethasone might decrease insulin sensitivity and increase blood pressure through an endothelium-mediated mechanism.
INTRODUCTION
There is considerable evidence that abnormalities of glucose, insulin and lipoprotein metabolism occur more frequently in untreated hypertensive patients than in normotensive subjects. It could be argued that the relationship between high blood pressure and metabolic disorder are incidental, but, on the other hand, there is evidence that changes in glucose, insulin and lipoprotein metabolism play a role in the etiopathology and/or clinical course of hypertension. In human hypertension subtle changes in adrenal steroid metabolism has been suggested (28, 29, 36) indicating that glucocorticoids, besides the well known Cushing syndrome, might have an important role in the development of high blood pressure. Moreover glucocorticoids have been shown to reduce cellular glucose uptake affecting the glucose transport system per-se (7), with no direct effects on the insulin receptor (26). Thus glucocorticoids alter glucose metabolism and in turn they have a role in the development of peripheral insulin resistance. Insulin resistance may be an impetus for the development of hypertension, impaired carbohydrate tolerance and lipids alteration, but the underlying mechanisms are still unclear. Similar metabolic abnormalities occur in rodent models of hypertension. For example, endothelial dysfunction precedes hypertension in an experimental model of fructose-induced insulin resistance (9, 24) , but fructose-induced insulin resistance is not easily comparable to humans. At the best of our knowledge there is no established model of insulin resistance induced by dexamethasone without the dramatic catabolic side effects commonly seen with glucocorticoids. We previously showed that it is possible to increase blood pressure for long term in rats with subcutaneous doses of dexamethasone in the order of micrograms/day (31) without appreciable catabolic effects. This animal model is not associated with sodium retention, but with sodium shift from the intracellular to the extracellular space (12), and the effects on blood pressure is opposite to those obtained by intracerebroventricular dexamethasone administration (32). The main aim of this study was to establish if our previously described "old model" of glucocorticoids induced hypertension in the rat is indeed an useful "new" model to studying insulin resistance in the metabolic syndrome. To do so we used our previously described animal model (31) evaluating the effects of metformin, a well-established drug able to ameliorate insulin sensibility in rat (25)
RESEARCH DESIGN AND METHODS

EXPERIMENT 1
ANIMALS
Male Wistar rats, 400 grams weight, were used through the experiments in groups of 6-7 animals each. All rats were housed in an automatically light-controlled animal facility (12hours on, 12 hours off) with constant temperature ( 22 C°) and humidity, with free access to food (Mil mice and rats GLP Diets, Mucedola Srl, Italy) and tap water ab libitum. Two weeks before starting the experiment animals were accustomed to handling, blood pressure and blood glucose measurements (by a vein puncture in the tail). Four groups were thereafter treated for 4 weeks:
A)
Vehicle: tap water and daily subcutaneous injection of 0.9% NaCl (75 µl) at 8.00 a.m and 8.00 pm, B) DEX: tap water and daily subcutaneous injections of Dexamethasone (1 µg in 75 µl 0.9% NaCl) at 8.00 a.m and 8.00 pm, C) MET: Metformin in tap water (3.5 mg/ml) and daily subcutaneous injection of 0.9% NaCl (75 µl) at 8.00 a.m and 8.00 pm, D) DEX+MET: metformin dissolved in tap water (3.5 mg/ml ) and. daily subcutaneous injection of Dexamethasone (1 µg in 75 µl 0.9% NaCl) at 8.00
a.m and 8.00 pm,
METHODS
Three times a week systolic blood pressure was measured in the morning (tail cuff Method, Letica, Le 5001 Pressure Meter, Spain) in the conscious lightly restrained animal after the animals being pre-warmed at 38 C° for 10 minutes as previously described (12, 31, 32) , body weight and tap water consumption were recorded at the same time. At days +8, +14 and +26 after blood pressure measurement, in the 6 conscious rats blood from a tail vein was obtained for glucose measurement using a Thus in this second experiment,Arginine was given as substrate of NOS for the production of nitric oxide (NO), while isosorbide dinitrate was given as direct NO donor, in order to establish the role of endothelium in this animal model. Animals were studied as in experiment 1 including insulin tolerance test evaluation. After 1 and 4 weeks treatment, immediately after blood pressure measurements, 2 ml blood were obtained from the tail in the conscious rat for biochemistry determination and haematocrit.
Statistical analysis
Data are presented as mean±SEM. After ANOVA measurements, with pair wise Newman-Keul's test for multiple comparisons, parameters found significantly different were subsequently analysed with the paired (within groups, different times)
or unpaired (between groups, same time) two tail Student t-test when appropriate, p<0.05 was taken as significant. Data were analysed using Sigma Stat 3.0 program.
Principles of laboratory animal care (NIH publication n°86-23, 1985) were followed in these experiments.
RESULTS
EXPERIMENT 1
All rats completed the 28 days experiments. Water consumption was equal in the groups (32-38 ml /day/ rat) a part for a slight decrease limited only between day +1
and +2 for rats receiving metformin. Both DEX+MET and MET rats drunk 21-26ml/day/rat during these days, probably due to the rats accustoming to the drug taste, thereafter the daily water intake was similar to that one of the other groups.
Thus the average metformin intake in the DEX+MET and MET rats was 183-228 mg/Kg/day for day 1 to 2 and 280-333 mg/Kg for the remaining days. Systolic blood pressure increased significantly only in DEX rats from day + 15, reaching the zenith at day +18 and remaining significantly elevated till day +28 with a net increase of more than 20 mmHg from basal (Figure 2 , top). The remaining rats did not show significant changes in SBP through the study although final SBP in DEX+MET rats was somehow 5 mmHg more elevated, but not significantly, than in the other two remaining groups (Vehicle and MET). Heart rate did not show significant difference during the study in the four groups of rats (Table 1) . Body weight did not change significantly through the study in any group (Table 1) . At the end of the 4 weeks serum insulin was significantly increased in DEX rats and decreased in metformin rats as compared to vehicle while blood glucose was equal in the four groups (Table   1) , Dexamethasone treated rats showed also significantly lower (p=0.032) levels of serum total nitrates/nitrites while haematocrit, cholesterol, triglycerides, FFA and insulin were significantly higher as compared to vehicle (Table 1) . These effects were completely reversed by the concomitant use of metformin (DEX+MET), but serum cholesterol remained higher than in vehicle. No significant changes for the other considered parameters were evident among the different groups of animals 11 included intraerythrocyte Na+ (12.1 ± 1.3, 10.4 ± 0.5, 9.8 ± 0.8, 12.5 ± 1.4, mEq/ 10 6 RBC for Vehicle, MET, DEX and DEX+ MET treated rats respectively).
Insulin sensitivity as estimated by the 30 minutes drop of blood glucose after i.p. fast acting insulin, was significantly reduced in DEX treated rats as compared to the other groups at time +8, +12 and +26 (Figure 2,bottom) . Similar results were obtained when insulin sensitivity was estimated by the steady-state plasma glucose during insulin/glucose infusion. Mean steady-state glycemia during the third hour insulin/glucose infusion was significantly higher in DEX rats as compared to DEX+MET: 128±6 vs 84±5 mg/dl, p< 0.02, while serum insulin at the end of the three hours infusion was comparable in the two groups.
At the end of the study no significant difference in heart, liver and kidney weight (corrected for body weight) was evident in the four groups of rats. Glycogen content, determined histological in the hepatocytes was reduced in Dexamethasone treated rats as compared to vehicle and metformin only treated rats. Moreover in dexamethasone treated rats an increased deposit of lipids at the liver level was evident ( Figure 3 ). The addition of metformin in Dexamethasone rats partially restored the content of glycogen at the liver level, dramatically reducing the liver lipids content. No significant differences in the different groups of rats were evident regarding kidney structure although the glomerular apparatus in DEX rats appeared bigger than in the other groups (data not shown).
EXPERIMENT 2
All animals completed the 28 days experiment and water consumption was equal in the groups (30-37 ml /day/ rat) without significant changes in rats given both ARG or ISN as compared to vehicle or DEX. Rats treated with DEX+ISN did not show any significant change in systolic blood pressure, heart rate and body weight through the 28 days experiments as compared to vehicle (data for final measurement at day 28 are shown in table 3). ISN treatment in addition to DEX was also able to completely reverse the effects of dexamethasone treatment in terms of triglycerides, haematocrit and delta glycemia changes after intraperitoneal insulin (Table 2) . On the other hand, DEX+ARG treated rats did not significantly differed from dexamethasone-only treated rats (DEX, table 3). Thus only the direct NO donor ISN given in association with dexamethasone was able to restore the conditions seen in the vehicle group.
DISCUSSION
In the present paper we describe for the first time, at the best of our knowledge, a new animal model of glucocorticoid-induced insulin resistance possibly due to endothelial dysfunction. We previously showed that it is possible to increase blood pressure for long term in rats with subcutaneous doses of dexamethasone in the order of micrograms/day without appreciable catabolic effects and a complete inhibition of ACTH secretion (31) and without sodium retention (12). The main aim of this study was to establish if this "old model" of glucocorticoids induced hypertension is a useful "new" model to studying insulin resistance. Using our "pure glucocorticoid" (2), besides lowering glycaemia. It is well known that glucocorticoids alter insulin sensitivity and they have a role in altering glucose metabolism and blood pressure regulation. Most of the already described "glucocorticoids" animal models do not take into account catabolism, with muscle atrophy (6,17,37) and increased blood pressure that can affect the measurement of insulin sensitivity by altering peripheral blood flow. Moreover no data on the long-term glucocorticoid treatment are available as well regarding a possible endothelial involvement. We choose metformin as a well established (25), both in-vivo and in-vitro, drug therapy to ameliorate peripheral insulin resistance in rats, as well in humans. Its wide use in diabetes is mainly due to its effects on peripheral insulin action increasing glucose uptake and utilization (30) although recently a direct effect of metformin on restoring β-cell insulin secretion response in vitro has been described. The reduction in blood pressure induced by metformin in insulin resistant rats is apparently through a direct mechanism with a nitric oxide-dependent relaxation (10). Indeed metformin has been shown able to attenuate the development of hypertension in the SHR (19) usually reported to be insulin resistant (4,17). These effects of metformin on blood pressure are not present in other animal models of hypertension not characterised by insulin resistance (38), indicating that metformin is not able per-se to decrease blood pressure.
An additional alternative "non-esterified fatty acid hypothesis" may be added to explain glucocorticoids induced insulin resistance (17). Our data show that dexamethasone treatment increase Free Fatty Acid (FFA) in plasma and this might have contributed to insulin resistance, while metformin treatment restores free fatty acid (FFA) metabolism (21), as we found in this experiment. Metformin increases the effects of infused L-Arginine on lowering blood pressure decreasing platelet aggregation and blood viscosity in NIDDM patients. We did not measure blood viscosity in our experiment, but metformin+dexamethasone (DEX+MET) rats showed, as compared to dexamethasone only treated rats (DEX), lower haematocrit levels, lower triglycerides, and lower FFA; all features that can explain a decrease in In conclusion the two most important finding of this study are: 1) long term -low dose subcutaneous dexamethasone induces insulin resistance that precedes hypertension and both conditions are reversed by the concomitant treatment with metformin, 2) dexamethasone induced insulin resistance might be due to endothelial dysfunction. Our data indicate that low-dose dexamethasone induced hypertension in rats, an "old model" (12,31,32) of hypertension, can be revisited on the light of an endothelial dysfunction causing insulin resistance and consequently some of the commonly observed features of the metabolic syndrome (hypertension, lipidmetabolism alteration, fatty liver etc). In particular the presence also of the hepatic consequences of the insulin resistance in humans (fatty liver) appears to complete the picture of metabolic syndrome due to reduced insulin sensitivity This model would be useful for studying the insulin resistance/blood pressure relationships. Table 2 Principal biochemical serum parameters, systolic blood pressure and body weight in the four groups of animals at day 7 and at the end of the 28 days experiment 2. SBP= systolic blood pressure, TG = triglycerides, FFA= Free Fatty Acids ∆% G= blood glucose variation (% from basal) after 1.6 U insulin Actrapid i.p. *P<0.05, **P<0.01, *** P<0.001 vs vehicle same day 
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